Who founded Cayuga Biotech?

Cayuga Biotech was founded by Damien Kudela, Kyle Ploense.

Who are Cayuga Biotech's investors?

Cayuga Biotech's investors include SOSV, Symbiotic Ventures, TBD Angels.

Cayuga Biotech

9 employees on LinkedIn · 3 known investors

Find your way into Cayuga Biotech

Each arrow is one introduction. Sign up to fill in the first one.

636 people can intro you to Damien

Ask Brooke Milton Vogel to introduce you to Damien Kudela

You →Brooke · together at U.S. Department of State →Damien

249 people can intro you to Kyle

Ask Jamie Chen to introduce you to Kyle Ploense

You →Jamie · together at Polygence →Kyle

216 people can intro you to Andrea

Ask Sam Okafor to introduce you to Andrea Ashford-Hicks

You →Sam · together at Enzyvant →Andrea

Your email: who you already know at Cayuga Biotech, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cayuga Biotech team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Cayuga Biotech is a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting-related conditions, with a lead candidate CAY001. It focuses on the hemostasis and thrombosis space, drawing on materials chemistry and translational medicine.

Biotech Healthtech Medical Devices

Founders & leadership

Damien Kudela Founder, Chief Science OfficerDamien Kudela holds a PhD in Materials Chemistry and previously worked in analysis for the US State Department. He founded Cayuga Biotech to develop hemostasis-promoting therapeutics, building on research from his doctoral work on nanoparticles designed to accelerate coagulation at injury sites.

Kyle Ploense Co-founderKyle Ploense is co-founder of Cayuga Biotech and has conducted research in neuroscience, hematology, and biosensing, with experience designing pre-clinical and clinical study protocols and IND-enabling toxicology and pharmacology studies for FDA submissions. He has over a decade of experience teaching and mentoring in academic and industry settings.

Andrea Ashford-Hicks Chief Executive OfficerAndrea Ashford-Hicks serves as Chief Executive Officer of Cayuga Biotech, a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting conditions. She brings over 20 years of biopharmaceutical experience, including involvement in 9 product launches and regulatory approvals (IND, BLA, NDA) at both large pharmaceutical and small biotech organizations.

Investors · 3

SOSVlisted by SOSVNew York · $30K – $550K

How we know: SOSV's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Symbiotic Ventureslisted by Symbiotic VenturesRidgewood

TBD Angelslisted by TBD AngelsNew York

Frequently asked questions

What does Cayuga Biotech do?: Cayuga Biotech is a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting-related conditions, with a lead candidate CAY001. It focuses on the hemostasis and thrombosis space, drawing on materials chemistry and translational medicine.
Who founded Cayuga Biotech?: Cayuga Biotech was founded by Damien Kudela, Kyle Ploense.
Who are Cayuga Biotech's investors?: Cayuga Biotech's investors include SOSV, Symbiotic Ventures, TBD Angels.